Tharimmune (NASDAQ:THAR) Trading 3% Higher – Should You Buy?

Shares of Tharimmune, Inc. (NASDAQ:THAR) traded up 3% during mid-day trading on Thursday . The stock traded as high as $2.11 and last traded at $2.06. 11,683 shares were traded during mid-day trading, a decline of 71% from the average session volume of 40,766 shares. The stock had previously closed at $2.00.

Analyst Ratings Changes

A number of brokerages recently commented on THAR. RODMAN&RENSHAW upgraded Tharimmune to a “strong-buy” rating in a report on Friday, December 6th. Rodman & Renshaw initiated coverage on shares of Tharimmune in a research note on Friday, December 6th. They issued a “buy” rating and a $17.00 price objective for the company.

Tharimmune Stock Performance

The business’s 50 day moving average is $2.09 and its 200 day moving average is $2.46.

Tharimmune (NASDAQ:THAR) last released its quarterly earnings data on Thursday, November 7th. The company reported ($2.45) earnings per share for the quarter.

Institutional Investors Weigh In On Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC bought a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned 2.06% of Tharimmune at the end of the most recent quarter. Institutional investors own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).